OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho-Vaxom (OM-85) for RTI Prevention at EAACI 2026

REACH study met its first primary endpoint, showing that Broncho-Vaxom (OM-85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 m...